

Supplementary Material

Appendix 1

Search Strategy for EMBASE, MEDLINE and Scopus

("Pseudoan*" OR "Pseudo-an" OR "False an*")

AND

("Femoral*" OR "Groin")

AND

("Intrav* drug use*" OR "Intrav* drug abuse*" OR "Intrav* drug misuse*" OR "Intrav* drug addict*" OR "Drug use*" OR "Drug abuse*" OR "Drug misuse*" OR "Drug addict*" OR "Substance use*" OR "Substance abuse*" OR "Substance misuse*" OR Inject* adj3 drug*)

Appendix 2

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Page No	Checklist item
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	1b	N/A	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	3	If registered, provide the name of the registry (such as PROSPERO) and registration number
Authors:			
Contact	3a	1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:			
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION			
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review

Information sources	9	8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	10	16	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:			
Data management	11a	8-10	Describe the mechanism(s) that will be used to manage records and data throughout the review
Selection process	11b	8-10	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	11c	8-10	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
Data items	12	9	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
Outcomes and prioritization	13	8,10	List and define all outcomes for which data will be sought, including prioritisation of main and additional outcomes, with rationale
Risk of bias in individual studies	14	10	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	15a	10	Describe criteria under which study data will be quantitatively synthesised
	15b	10	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)
	15c	10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)
	15d	N/A	If quantitative synthesis is not appropriate, describe the type of summary planned
Meta-bias(es)	16	N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)
Confidence in cumulative evidence	17	10	Describe how the strength of the body of evidence will be assessed (such as GRADE)

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

